Future studies should aim to clarify the relationship between GLP-1 agonist use and aspiration risk, including factors such as duration of use, type of GLP-1 agonist (short- vs. long-acting), and underlying comorbidities like diabetes and obesity. This evidence concerns the gene GLP1R and Obesity.